Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 7/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7368425 | 0.76 | DAO (0.71) | DAONPSR1CASP3SENP7SENP8 | |
| SCHEMBL10877089 | 0.74 | MEN1 (0.56) | DAOPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10635902 | 0.70 | PDE4A (0.47) | DAOPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5859674 | 0.68 | DAO (0.71) | DAONPSR1CASP3SENP7SENP8 | |
| SCHEMBL11065150 | 0.68 | DAO (0.45) | DAOPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10632503 | 0.67 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DNPSR1 | |
| SCHEMBL1612962 | 0.67 | — | — | |
| SCHEMBL130041 | 0.67 | — | — | |
| SCHEMBL3752532 | 0.66 | DAO (0.61) | DAONPSR1CYP3A4HPGDMEN1 | |
| SCHEMBL7339717 | 0.66 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803760-B2 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2010-09-28 | — | — | US | claimed |
| JP-4532115-B2 | — | — | 2010-08-25 | — | — | JP | claimed |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | MERCK SERONO SA (CH) | 2008-11-27 | — | — | US | claimed |
| US-6953774-B2 | Methods of inducing ovulation | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-10-11 | — | — | US | claimed |
| US-20050148501-A1 | Methods of inducing ovulation using a non-polypeptide camp level modulator | MERCK SERONO SA (CH) | 2005-07-07 | — | — | US | claimed |
| EP-1463493-A1 | METHODS OF INDUCING OVULATION-USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-06 | — | — | EP | claimed |
| WO-2003051344-A1 | METHODS OF INDUCING OVULATION_USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-06-26 | — | — | WO | claimed |
| US-20020103106-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2002-08-01 | — | — | US | claimed |
| EP-1908463-B1 | Methods of inducing ovulation using a non-polypeptide camp level modulator | MERCK SERONO SA (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-7803760-B2 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2010-09-28 | — | — | US | disclosed |
| US-7507707-B2 | Methods of inducing ovulation using a non-polypeptide camp level modulator | LABORATOIRES SERONO SA (CH) | 2009-03-24 | — | — | US | disclosed |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | MERCK SERONO SA (CH) | 2008-11-27 | — | — | US | disclosed |
| US-7364910-B2 | Methods of inducing ovulation | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| EP-1908463-A2 | Methods of inducing ovulation using a non-polypeptide camp level modulator | Laboratoires Serono SA (CH) | 2008-04-09 | — | — | EP | disclosed |
| US-20060003925-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2006-01-05 | — | — | US | disclosed |
| US-6953774-B2 | Methods of inducing ovulation | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-10-11 | — | — | US | disclosed |
| US-20050148501-A1 | Methods of inducing ovulation using a non-polypeptide camp level modulator | MERCK SERONO SA (CH) | 2005-07-07 | — | — | US | disclosed |
| EP-1463493-A1 | METHODS OF INDUCING OVULATION-USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003051344-A1 | METHODS OF INDUCING OVULATION_USING A NON-POLYPEPTIDE CAMP LEVEL MODULATOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-06-26 | — | — | WO | disclosed |
| US-20020103106-A1 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148501-A1 | Methods of inducing ovulation using a non-polypeptide camp level modulator | PDE4A, PDE4B, PDE4C | DAO 636/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20060003925-A1 | Methods of inducing ovulation | PDE4A, PDE4B, PDE4C | DAO 547/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20020103106-A1 | Methods of inducing ovulation | PDE4A, PDE4B, PDE4C | DAO 543/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20080293622-A1 | METHODS OF INDUCING OVULATION | PDE4A, PDE4B, PDE4C | DAO 547/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.